Leadership

For the necessary data for your NDA, ANDA, or 505(b)(2) NDA submission, you can count on Camargo’s end-to-end drug development and regulatory expertise. Our executive team are accomplished leaders in the full spectrum of drug development (pre-clinical, manufacturing, clinical, regulatory and commercial) and have extensive experience working in and with pharmaceutical, biotech and contract services organizations. Our practical knowledge of both the science and the business strategy of drug development streamlines the drug’s path-to-market.

Kenneth V. Phelps
President/CEO

Ruth E. Stevens, PhD, MBA
Chief Scientific Officer, Executive Vice President

William P. Stoltman, JD
Senior Director, Regulatory Affairs and Quality Assurance

Kathryn Wekselman, PhD, RN
Senior Director, Research Services

Stacey A. Ayres, PhD
Director, Scientific Research Services

Cynthia F. Phurrough
Director, Clinical Services

Jaber Qasem, PhD
Director, Pharmaceutics